Diabetes

Ocular conditions can lead to serious complications, and sometimes there are no early symptoms.

Metformin hydrochloride extended-release tablets are indicated to for improving glycemic control in patients with type 2 diabetes mellitus, as an adjunct to diet and exercise.

Clinical data has illustrated how digital interventions can have a substantial material benefit on glycemic control in users with diabetes, with 73 of 162 users in the study reducing their average blood glucose levels to under 140 mg/dL.

In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.

Top news of the day from across the health care landscape.

What is causing this patient to lose her sense of smell?

Pharmacists can help with product selection and counsel on routine self-monitoring.

Confirming latent autoimmune diabetes in adults and dispensing the correct tube size for triaminoclone.

This intervention fosters connections with patients, identifies treatment goals, and increases adherence.

Top news of the day from across the health care landscape.

Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.

Treatment depends on the patient, but adherence to the ever-changing guidelines is key.

A study has found that young adults with diabetes have high rates of cardiometabolic risk factors such as adiposity, blood pressure, chronic kidney disease, and history of cardiovascular disease. These risk factors can lead to an increased disease prevalence and mortality rate among these young adults as they age.

The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

The FDA has granted approval of Rybelsus (semaglutide) oral tablets 7 mg or 14 mg to Novo Nordisk. The drug is the first oral glucagon-like peptide (GLP-1) receptor protein treatment for type 2 diabetes.

A recent clinical study demonstrated positive long-term benefits of the early intervention combination treatment of metformin plus vildagliptin (Galvus, Norvartis), a dipeptidyl peptidase-4 [DPP-4] inhibitor, for type 2 diabetes (T2D).

The glucagon injection is designed to reduce the steps and time needed to prepare and administer medicine for severe hypoglycemia.

Recently published in Science Daily, the study was based on the investigating team’s analysis of more than 12 million reports from the FDA Adverse Effect Reporting System (FAERS) and Adverse Event Reporting System (AERS) databases.

Help pregnant women with diet, other lifestyle changes, prevention, symptoms, and treatment.

The FDA has granted Eli Lilly and Company approval for its nasal powder glucagon (Baqsimi) for emergency treatment of severe hypoglycemia.

A day after stakeholders told a House of Representatives subcommittee about problems accessing and paying for insulin, Cigna and its pharmacy benefit manager Express Scripts said they are launching a program for patients with diabetes in their commercial plans so that they pay no more than $25 for a 30-day supply of insulin.

The drug is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. It is only intended to use in acute care settings under medical supervision.

Why does this woman have excessive facial and neck movements?

Retina Risk is a new app that patients can use to help screen for their risk of retinopathy.

The drug is earned the designation for reducing the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

According to the CDC, approximately 1 of 3 patients with type 1 and 2 diabetes mellitus (DM) has CKD. What do we need to know about patients with DM and CKD?

Liraglutide is the first noninsulin drug approved to treat T2D in pediatric patients since metformin was approved for pediatric use in 2000, according to the FDA.

Officials with the FDA today approved liraglutide (Victoza, Novo Nordisk) injection for treatment of pediatric patients age 10 years or older with type 2 diabetes (T2D).

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new subgroup analysis from the phase 3 CREDENCE study,